作者
Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, Anurag Garg, Victoria Vickerstaff, Rachael Hunter, Gareth Ambler, Catey Bunce, Richard Wormald, Neil Nathwani, Keith Barton, Gary Rubin, Marta Buszewicz, Rupert Bourne, David Broadway, Amanda Davis, Hari Jayaram, Yuzhen Jiang, Sheng Lim, Joanna Liput, Timothy Manners, Stephen Morris, Nicholas Strouthidis, Sarah Wilson, Haogang Zhu
发表日期
2019/4/13
期刊
The Lancet
卷号
393
期号
10180
页码范围
1505-1516
出版商
Elsevier
简介
Background
Primary open angle glaucoma and ocular hypertension are habitually treated with eye drops that lower intraocular pressure. Selective laser trabeculoplasty is a safe alternative but is rarely used as first-line treatment. We compared the two.
Methods
In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. They were randomly allocated (web-based randomisation) to initial selective laser trabeculoplasty or to eye drops. An objective target intraocular pressure was set according to glaucoma severity. The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. Analysis was by intention to treat. This …
学术搜索中的文章
G Gazzard, E Konstantakopoulou, D Garway-Heath… - The Lancet, 2019